N/A
N=12
Progressive Strength Training in Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Bottom Line
View on ClinicalTrials.gov: NCT01233817 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Mar 2013
Primary outcome: Primary: Strength — 0.39 kilograms
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Progressive strength training (Other)
- Age
- Pediatric, Adult · 5+ yrs
- Sex
- All
- Sponsor
- University of Utah
- Primary completion
- Jun 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Strength |
0.39 | — |
Summary
The proposed feasibility study is necessary to test if children and young adults will participate in and adhere to a 12-week, home-based, supervised progressive strength training exercise program and to obtain preliminary data that will subsequently allow us to determine the safety and impact of strength training in spinal muscular atrophy. Our pilot study will address 3 aims: (1) Ascertain the feasibility of, and potential barriers to, participation in and adherence to a 12-week home-based, supervised, progressive strength training exercise program in children and young adults aged 5-21 years with SMA types II and III; (2) Determine the safety and tolerability of progressive strength training in a pilot study sample of children and young adults with SMA types II and III; and (3) Determine candidate outcome measures.
Eligibility Criteria
Inclusion Criteria
- age 5-21 years
- diagnosis of SMA type II or III
- at least antigravity strength in elbow flexors
- ability to follow commands and stay on task
- place of residence within a 60-minute or 60-mile drive of the University of Utah
Exclusion Criteria
- planned surgery or out-of-town trips during the proposed intervention period
- inability to travel to study center for testing
- neurological diagnosis other than SMA
Data sourced from ClinicalTrials.gov (NCT01233817). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.